Ipsen bets up to $363M on an­oth­er shot at a de­bil­i­tat­ing con­di­tion re­lat­ed to Parkin­son's dis­ease

Ipsen is in a deal-mak­ing mood. On Thurs­day, the com­pa­ny put down $28 mil­lion up­front and an­oth­er $335 mil­lion in biobucks for the rights to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA